Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
Nine-Year Follow-Up After M-TEER for Secondary Mitral Regurgitation in a Patient With Cardiogenic Shock.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Reithmayer Tobias, Stocker Thomas J, Weckbach Ludwig T, Novotny Julia, Doldi Philipp M, Kempton Hannah, Massberg Steffen, Näbauer Michael, Hausleiter Jörg, Stolz Lukas
Аннотация
BACKGROUND: Transcatheter edge-to-edge repair (TEER) has become an established therapeutic option for patients with severe secondary mitral regurgitation (SMR). While randomized trials and registry data have reported outcomes up to 5 years, longer follow-up data remain scarce.
CASE SUMMARY: We report the case of a 48-year-old male patient who was admitted to our hospital with cardiogenic shock, first diagnosis of dilated cardiomyopathy and severe ventricular SMR in August 2016. With the use of mechanical circulatory support, the patient underwent urgent M-TEER with implantation of one MitraClip device, reducing MR from severe to mild-to-moderate. At 9-year follow-up in 2025 and consequent optimization of guideline directed medical therapy, the patient remains clinically stable, with sustained MR reduction and good device function.
DISCUSSION: This case highlights the durability of M-TEER even in a critically ill patient initially presenting with cardiogenic shock and multiorgan failure. To our knowledge, this represents one of the longest follow-up observations after M-TEER, supporting its role as a durable treatment strategy in high-risk patients.
CONCLUSIONS: M-TEER can achieve durable long-term MR reduction and symptomatic benefit.
CASE SUMMARY: We report the case of a 48-year-old male patient who was admitted to our hospital with cardiogenic shock, first diagnosis of dilated cardiomyopathy and severe ventricular SMR in August 2016. With the use of mechanical circulatory support, the patient underwent urgent M-TEER with implantation of one MitraClip device, reducing MR from severe to mild-to-moderate. At 9-year follow-up in 2025 and consequent optimization of guideline directed medical therapy, the patient remains clinically stable, with sustained MR reduction and good device function.
DISCUSSION: This case highlights the durability of M-TEER even in a critically ill patient initially presenting with cardiogenic shock and multiorgan failure. To our knowledge, this represents one of the longest follow-up observations after M-TEER, supporting its role as a durable treatment strategy in high-risk patients.
CONCLUSIONS: M-TEER can achieve durable long-term MR reduction and symptomatic benefit.